CGPCS
RARE icon

Capital Group Private Client Services’s Ultragenyx Pharmaceutical RARE Stock Holding History

Capital Group Private Client Services’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-57,963
Closed -$4.87M – 245
2021
Q4 		$4.87M Sell
57,963
-2,221
-4% -$181K 0.05% 150
2021
Q3 		$5.43M Buy
+60,184
New +$5.44M 0.06% 146

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital Group Private Client Services's RARE Position: Q1 2022 in Review

Capital Group Private Client Services sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2022, closing a stake of 57,963 shares — an estimated $4.87M sold.

Capital Group Private Client Services first reported a position in RARE in Q3 2021 and held it in 2 quarters. The position peaked at $5.43M in Q3 2021. 240 funds tracked by Wall St. Rank hold RARE as of Q1 2022.

  • Capital Group Private Client Services reported no remaining Ultragenyx Pharmaceutical position as of Q1 2022 after selling out during the quarter.
  • Capital Group Private Client Services sold 57,963 Ultragenyx Pharmaceutical shares in Q1 2022, an estimated $4.87M.
  • Capital Group Private Client Services first reported a position in Ultragenyx Pharmaceutical in Q3 2021 and held it in 2 quarters.
  • Capital Group Private Client Services's Ultragenyx Pharmaceutical position peaked at $5.43M in Q3 2021.
  • 240 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2022.

Based on Capital Group Private Client Services's 13F filing for Q1 2022, filed 16 May 2022.